Synlogic finalizes Mirna Therapeutics merger

Synlogic said today that it finished its merger with Mirna Therapeutics after the deal won approval from Mirna’s stockholders last week.

The merged company, which will trade on the Nasdaq market under the symbol “SYBX”, is slated to advance Synlogic’s Synthetic Biotic medicines. The company’s platform uses synthetic biology to reprogram probiotic bacteria to treat metabolic and inflammatory diseases.

Get the full story at our sister site, Drug Delivery Business News.

The post Synlogic finalizes Mirna Therapeutics merger appeared first on MassDevice.

from MassDevice http://ift.tt/2vm0Mjj